| Cortot, Alexis |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel | Seagen Inc. | Carcinoma, Non-Small-Cell Lung | 07/26 | 07/28 | | |
DIAL, NCT05255302 / 2021-006044-27: De-escalation Immunotherapy MAintenance Duration Trial for Stage IV Lung Cancer Patients with Disease Control After Chemo-immunotherapy Induction |
|
|
| Recruiting | 2/3 | 1360 | Europe | Pembrolizumab before randomization, Chemotherapy, Pemetrexed, Pembrolizumab after randomization | Intergroupe Francophone de Cancerologie Thoracique, IFCT | Metastatic NSCLC | 01/25 | 06/29 | | |
GFPC 06-2018, NCT04042558 / 2019-000727-41: A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies |
|
|
| Recruiting | 2 | 149 | Europe | Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab, Carboplatin + Pemetrexed + Atezolizumab | Centre Francois Baclesse, GFPC | NSCLC Stage IIIB, NSCLC Stage IV, EGFR Gene Mutation, ALK Gene Rearrangement Positive, ROS1 Gene Mutation | 10/21 | 06/25 | | |
ORBITAL, NCT04233021: Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation |
|
|
| Active, not recruiting | 2 | 57 | Europe | Osimertinib | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer Metastatic, Leptomeningeal Metastasis, Brain Metastases, EGFR Activating Mutation | 03/23 | 12/24 | | |
ORAKLE, NCT04111705: Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients with Advanced ALK-positive Non-small Cell Lung Cancer |
|
|
| Active, not recruiting | 2 | 23 | Europe | Lorlatinib | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer Metastatic | 01/25 | 01/25 | | |
| Recruiting | 2 | 119 | Europe | Encorafenib 75 MG, Binimetinib 15 MG | Intergroupe Francophone de Cancerologie Thoracique, IFCT, Pierre Fabre | Non Small Cell Lung Cancer, BRAF V600E | 12/24 | 03/26 | | |
|
MELROSE, NCT03865511: MEchanisms of Resistance in EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtib |
|
|
| Active, not recruiting | 2 | 150 | Europe | TAGRISSO® 80mg (Osimertinib), Tumor biopsies, ctDNA analysis | Nantes University Hospital, AstraZeneca | Non-small Cell Lung Cancer | 01/25 | 01/25 | | |
REPOROS, NCT06552234: Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC |
|
|
| Not yet recruiting | 2 | 30 | Europe | Repotrectinib | Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer, Groupe Français de Pneumo-Cancérologie, Hospices Civils de Lyon | NSCLC Stage IV, NSCLC, Stage III | 09/31 | 09/31 | | |
NCT04621188: Lorlatinib After Failure of First-line TKI in Patients with Advanced ROS1-positive NSCLC (ALBATROS) |
|
|
| Recruiting | 2 | 84 | Europe | Lorlatinib | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer Metastatic | 03/25 | 01/26 | | |
| Active, not recruiting | 2 | 110 | Europe | Brigatinib 180 MG, ALUNBRIG, Carboplatin, Pemetrexed | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer, ALK Gene Mutation | 04/25 | 10/28 | | |
| Recruiting | 2 | 70 | Europe, US | IPH5201 + durvalumab + standard chemotherapy, Durvalumab, MEDI4736, IMFINZI, Carboplatin/Paclitaxel Carboplatin/Paclitaxel, as chemotherapy, Pemetrexed/Cisplatin Pemetrexed/Cisplatin as chemotherapy, Pemetrexed/Carboplatin Pemetrexed/Carboplatin as chemotherapy | Innate Pharma | Non Small Cell Lung Cancer | 06/25 | 09/26 | | |
RAMP 203, NCT05074810: Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients |
|
|
| Recruiting | 1/2 | 153 | Europe, US | avutometinib and sotorasib, AMG 510, LUMAKRAS™, VS-6766, avutometinib and sotorasib and defactinib, VS-6063 | Verastem, Inc., Amgen | Non Small Cell Lung Cancer, KRAS Activating Mutation | 09/25 | 04/27 | | |
NCT05752552: Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients with Advanced or Refractory Solid Tumours |
|
|
| Recruiting | 1 | 25 | Europe | DO-2 | DeuterOncology | Adult Solid Tumor, Advanced Solid Tumor, Refractory Tumor, Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Lung Cancer, Hereditary Renal Papillary Cancer | 12/25 | 12/26 | | |
| Completed | N/A | 179 | Europe, Canada, RoW | | Takeda | Non-small Cell Lung Cancer (NSCLC) | 02/23 | 02/23 | | |
EmoVie_K2, NCT04556344: Effectiveness of an Educational Intervention Aimed at Increasing the Emotional Competencies of Patients Under Surveillance After Antineoplastic Treatment of Oesogastric or Bronchopulmonary Cancer |
|
|
| Recruiting | N/A | 86 | Europe | Emotional skills, Short free talk and relaxation | University Hospital, Lille, SCALab UMR CNRS 9193 | Digestive System Neoplasms, Thoracic Neoplasms | 10/23 | 10/23 | | |
CIRCULAR, NCT04912687: Implementing Circulating Tumor DNA Analysis at Initial Diagnosis to Improve Management of Advanced NSCLC Patients |
|
|
| Recruiting | N/A | 580 | Europe | EGFR gene mutation analysis on liquid biopsy | Institut Bergonié, AstraZeneca | Non Small Cell Lung Cancer, Advanced Solid Tumor | 01/25 | 01/26 | | |
| Recruiting | N/A | 700 | Europe, Canada, US, RoW | | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Cancer | 03/27 | 03/27 | | |
| Recruiting | N/A | 100 | Europe | RNAseq, DNA NGS | Groupe Francais De Pneumo-Cancerologie, Takeda | Non-small Cell Lung Cancer, ALK Gene Rearrangement Positive | 06/27 | 06/27 | | |
ROSIE, NCT06053099: A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19) |
|
|
| Recruiting | N/A | 300 | Europe | Plasma ctDNA, FFPE blocks | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer, EGFR Activating Mutation, EGFR DEL19, EGFR L858R | 10/31 | 10/31 | | |
| Recruiting | N/A | 500 | Europe | tissue biopsies, blood sampling, DNA banking | University Hospital, Lille, Institut Pasteur de Lille, University of Lille Nord de France | Lung Cancer | 03/32 | 03/32 | | |
